Works by Zhang, Liling


Results: 98
    1
    2
    3
    4
    5

    Emergence and ongoing outbreak of ST80 vancomycin-resistant Enterococcus faecium in Guangdong province, China from 2021 to 2023: a multicenter, time-series and genomic epidemiological study.

    Published in:
    Emerging Microbes & Infections, 2024, v. 13, n. 1, p. 1, doi. 10.1080/22221751.2024.2361030
    By:
    • Cong Shen;
    • Li Luo;
    • Hongyun Zhou;
    • Yinglun Xiao;
    • Jinxiang Zeng;
    • Liling Zhang;
    • Jieying Pu;
    • Jianming Zeng;
    • Ni Zhang;
    • Yueting Jiang;
    • Lingqing Xu;
    • Dingqiang Chen;
    • Gang Li;
    • Kuihai Wu;
    • Hua Yu;
    • Min Wang;
    • Xuemin Guo;
    • Juan Wang;
    • Bin Huang;
    • Cha Chen
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12

    Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study.

    Published in:
    Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00462-z
    By:
    • Zha, Jie;
    • Chen, Qinwei;
    • Ye, Jingjing;
    • Yu, Haifeng;
    • Yi, Shuhua;
    • Zheng, Zhong;
    • Xu, Wei;
    • Li, Zhifeng;
    • Ping, Lingyan;
    • He, Xiaohua;
    • Zhang, Liling;
    • Li, Caixia;
    • Xie, Ying;
    • Chen, Feili;
    • Sun, Xiuhua;
    • Su, Liping;
    • Zhang, Huilai;
    • Fan, Liyuan;
    • Lin, Zhijuan;
    • Yang, Haiyan
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20

    First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11268-5
    By:
    • Zhong, Kaili;
    • Shi, Yanyan;
    • Gao, Yuhuan;
    • Zhang, Huilai;
    • Zhang, Mingzhi;
    • Zhang, Qiaohua;
    • Cen, Xinan;
    • Xue, Mei;
    • Qin, Yan;
    • Zhao, Yu;
    • Zhang, Liling;
    • Liang, Rong;
    • Wang, Ningju;
    • Xie, Yan;
    • Yang, Yu;
    • Liu, Aichun;
    • Bao, Huizheng;
    • Wang, Jingwen;
    • Cao, Baoping;
    • Zhang, Wei
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup>) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

    Published in:
    Hematological Oncology, 2022, v. 40, n. 5, p. 930, doi. 10.1002/hon.3054
    By:
    • Shi, Yuankai;
    • Zhang, Qingyuan;
    • Hong, Xiaonan;
    • Wang, Zhen;
    • Gao, Yuhuan;
    • Zou, Liqun;
    • Cen, Hong;
    • Gui, Lin;
    • Li, Yufu;
    • Feng, Jifeng;
    • Wang, Zhao;
    • Zhang, Mingzhi;
    • Jin, Chuan;
    • Zhang, Weihua;
    • Hu, Jianda;
    • Zheng, Chengyun;
    • Zheng, Zhendong;
    • Zhang, Liling;
    • Chen, Shaoshui;
    • Huang, Yunhong
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50